600420 国药现代
已收盘 12-19 15:00:00
资讯
新帖
简况
国药现代（600420）披露拟变更经营范围并修订公司章程，12月15日股价上涨0.1%
证券之星 · 12-15
国药现代（600420）披露拟变更经营范围并修订公司章程，12月15日股价上涨0.1%
国药现代（600420）披露全资子公司获得药品注册证书，12月11日股价上涨0.79%
证券之星 · 12-11
国药现代（600420）披露全资子公司获得药品注册证书，12月11日股价上涨0.79%
国药现代(600420.SH)：布美他尼注射液获得药品注册证书
智通财经 · 12-11
国药现代(600420.SH)：布美他尼注射液获得药品注册证书
国药现代（600420）披露全资孙公司获得化学原料药上市申请批准通知书，12月9日股价下跌0.78%
中金财经 · 12-10
国药现代（600420）披露全资孙公司获得化学原料药上市申请批准通知书，12月9日股价下跌0.78%
国药现代(600420.SH)：原料药阿戈美拉汀上市申请获批准
智通财经 · 12-09
国药现代(600420.SH)：原料药阿戈美拉汀上市申请获批准
国药现代（600420）披露独立董事候选人提名公告，12月8日股价下跌0.48%
证券之星 · 12-08
国药现代（600420）披露独立董事候选人提名公告，12月8日股价下跌0.48%
国药现代(600420.SH)子公司获盐酸氢吗啡酮注射液药品注册证书
智通财经 · 11-28
国药现代(600420.SH)子公司获盐酸氢吗啡酮注射液药品注册证书
每周股票复盘：国药现代（600420）选举王香芬为职工董事
证券之星 · 11-23
每周股票复盘：国药现代（600420）选举王香芬为职工董事
国药现代（600420）披露选举职工董事公告，11月21日股价下跌2.21%
证券之星 · 11-21
国药现代（600420）披露选举职工董事公告，11月21日股价下跌2.21%
每周股票复盘：国药现代（600420）将参加三季报业绩说明会
证券之星 · 11-09
每周股票复盘：国药现代（600420）将参加三季报业绩说明会
国药现代：公司持续加强与国药控股分销、零售等渠道的合作
证券日报 · 11-05
国药现代：公司持续加强与国药控股分销、零售等渠道的合作
国药现代（600420）披露参加2025年上海辖区上市公司三季报集体业绩说明会的公告，11月05日股价上涨0.1%
证券之星 · 11-05
国药现代（600420）披露参加2025年上海辖区上市公司三季报集体业绩说明会的公告，11月05日股价上涨0.1%
国药现代(600420.SH)控股子公司签署《药品上市许可转让合同》
智通财经 · 11-03
国药现代(600420.SH)控股子公司签署《药品上市许可转让合同》
每周股票复盘：国药现代（600420）Q3净利降45.31%
证券之星 · 11-02
每周股票复盘：国药现代（600420）Q3净利降45.31%
股市必读：国药现代(600420)股东户数3.78万户，较上期减少5.26%
证券之星 · 10-31
股市必读：国药现代(600420)股东户数3.78万户，较上期减少5.26%
图解国药现代三季报：第三季度单季净利润同比下降45.31%
证券之星 · 10-29
图解国药现代三季报：第三季度单季净利润同比下降45.31%
国药现代最新公告：公司及下属子公司拟中选第十一批全国药品集中采购
证券之星 · 10-28
国药现代最新公告：公司及下属子公司拟中选第十一批全国药品集中采购
国药现代最新公告：全资子公司国药容生盐酸林可霉素注射液通过仿制药一致性评价
证券之星 · 10-27
国药现代最新公告：全资子公司国药容生盐酸林可霉素注射液通过仿制药一致性评价
每周股票复盘：国药现代（600420）国药容生法莫替丁注射液通过一致性评价
证券之星 · 10-19
每周股票复盘：国药现代（600420）国药容生法莫替丁注射液通过一致性评价
国药现代（600420）披露全资子公司药品通过仿制药一致性评价，10月17日股价下跌1.11%
证券之星 · 10-17
国药现代（600420）披露全资子公司药品通过仿制药一致性评价，10月17日股价下跌1.11%
公司概况
公司名称：
上海现代制药股份有限公司
所属行业：
医药制造业
上市日期：
2004-06-16
主营业务：
上海现代制药股份有限公司的主营业务是医药产品研发、生产与销售。公司的主要产品是医药中间体、原料药、化学制剂、动物疫苗、大健康。至报告期末，公司累计通过一致性评价项目（含视同）151个，其中通过自主研发和BD项目引进获得新产品批准文号59个。
发行价格：
8.08
{"stockData":{"symbol":"600420","market":"SH","secType":"STK","nameCN":"国药现代","latestPrice":10.33,"timestamp":1766127600000,"preClose":10.29,"halted":0,"volume":6534240,"delay":0,"changeRate":0.0039,"floatShares":1341000000,"shares":1341000000,"eps":0.6937,"marketStatus":"已收盘","change":0.04,"latestTime":"12-19 15:00:00","open":10.31,"high":10.37,"low":10.27,"amount":67508800,"amplitude":0.0097,"askPrice":10.33,"askSize":277,"bidPrice":10.32,"bidSize":38,"shortable":0,"etf":0,"ttmEps":0.6937,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1766367000000},"marketStatusCode":5,"adr":0,"adjPreClose":10.29,"symbolType":"stock","openAndCloseTimeList":[[1766107800000,1766115000000],[1766120400000,1766127600000]],"highLimit":11.32,"lowLimit":9.26,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1341172692,"isCdr":false,"pbRate":1.02,"roa":"--","peRate":14.891163,"roe":"5.93%","epsLYR":0.808,"committee":-0.187704,"marketValue":13854000000,"turnoverRate":0.0049,"status":0,"floatMarketCap":13854000000},"requestUrl":"/m/hq/s/600420/wiki","defaultTab":"wiki","newsList":[{"id":"2591642601","title":"国药现代（600420）披露拟变更经营范围并修订公司章程，12月15日股价上涨0.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2591642601","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591642601?lang=zh_cn&edition=full","pubTime":"2025-12-15 22:24","pubTimestamp":1765808652,"startTime":"0","endTime":"0","summary":"截至2025年12月15日收盘，国药现代报收于10.26元，较前一交易日上涨0.1%，最新总市值为137.6亿元。该股当日开盘10.22元，最高10.29元，最低10.18元，成交额达4969.98万元，换手率为0.36%。近日，国药现代发布2025年第三次临时股东会会议资料，公告显示公司拟召开2025年第三次临时股东会，审议变更经营范围并修订《公司章程》的议案。此外，会议还涉及修订《对外担保管理制度》以及选举第九届董事会非独立董事和独立董事等相关议案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121500035864.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0020","BK0239","BK0082","BK0010","600420","BK0132"],"gpt_icon":0},{"id":"2590511086","title":"国药现代（600420）披露全资子公司获得药品注册证书，12月11日股价上涨0.79%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590511086","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590511086?lang=zh_cn&edition=full","pubTime":"2025-12-11 22:18","pubTimestamp":1765462695,"startTime":"0","endTime":"0","summary":"截至2025年12月11日收盘，国药现代报收于10.24元，较前一交易日上涨0.79%，最新总市值为137.34亿元。该股当日开盘10.19元，最高10.29元，最低10.12元，成交额达8676.17万元，换手率为0.63%。2024年全国公立医疗机构销售额为46,887万元。截至目前，国药容生该项目累计研发投入约462万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121100041720.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0132","BK0020","BK0010","600420","BK0082"],"gpt_icon":0},{"id":"2590595903","title":"国药现代(600420.SH)：布美他尼注射液获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2590595903","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590595903?lang=zh_cn&edition=full","pubTime":"2025-12-11 16:35","pubTimestamp":1765442101,"startTime":"0","endTime":"0","summary":"智通财经APP讯，国药现代(600420.SH)发布公告，近日，公司全资子公司国药集团容生制药有限公司(以下简称国药容生)收到国家药品监督管理局核准签发的布美他尼注射液《药品注册证书》。本次国药容生的布美他尼注射液获得药品注册证书并视同通过一致性评价，丰富了公司心血管药物产品群，有利于进一步增强公司在相关用药领域的综合市场竞争力，为公司未来发展带来积极影响。上述事项对公司当期经营业绩不会产生重大影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1380363.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"国药现代(600420.SH)：布美他尼注射液获得药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0082","BK0020","BK0132","600420","BK0010","BK0239"],"gpt_icon":0},{"id":"2590455378","title":"国药现代（600420）披露全资孙公司获得化学原料药上市申请批准通知书，12月9日股价下跌0.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590455378","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590455378?lang=zh_cn&edition=full","pubTime":"2025-12-10 08:05","pubTimestamp":1765325153,"startTime":"0","endTime":"0","summary":"近日，国药现代发布公告称，公司全资孙公司江苏威奇达药业有限公司收到国家药品监督管理局签发的关于原料药阿戈美拉汀的《化学原料药上市申请批准通知书》，批准号为2025YS01091，登记号Y20240000572，注册标准编号YBY73032025，包装规格20kg/桶。该原料药符合药品注册相关要求，可在境内生产销售。此次获批不会对公司当期经营业绩产生重大影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20251210/31854885.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0082","BK0020","BK0132","600420","BK0010","BK0239"],"gpt_icon":0},{"id":"2590340316","title":"国药现代(600420.SH)：原料药阿戈美拉汀上市申请获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2590340316","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590340316?lang=zh_cn&edition=full","pubTime":"2025-12-09 16:26","pubTimestamp":1765268771,"startTime":"0","endTime":"0","summary":"智通财经APP讯，国药现代(600420.SH)公告，公司全资孙公司江苏威奇达药业有限公司(简称国药江苏威奇达)收到国家药品监督管理局核准签发的关于原料药阿戈美拉汀的《化学原料药上市申请批准通知书》。阿戈美拉汀主要通过对褪黑素受体MT1、MT2的激动及对5-HT2C拮抗的协同作用，而使患者紊乱的生物节律恢复正常，进而发挥抗抑郁效应，其制剂产品临床主要用于治疗成年抑郁症。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1379298.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"国药现代(600420.SH)：原料药阿戈美拉汀上市申请获批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0020","BK0239","BK0132","BK0010","BK0082","600420"],"gpt_icon":0},{"id":"2589135999","title":"国药现代（600420）披露独立董事候选人提名公告，12月8日股价下跌0.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2589135999","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589135999?lang=zh_cn&edition=full","pubTime":"2025-12-08 22:20","pubTimestamp":1765203635,"startTime":"0","endTime":"0","summary":"截至2025年12月8日收盘，国药现代报收于10.28元，较前一交易日下跌0.48%，最新总市值为137.87亿元。该股当日开盘10.33元，最高10.37元，最低10.27元，成交额达7103.54万元，换手率为0.51%。近日，上海现代制药股份有限公司董事会发布公告，提名邵瑞庆为公司第九届董事会独立董事候选人。公告显示，邵瑞庆具备独立董事任职资格，具有5年以上会计、财务等相关工作经验，拥有会计学教授职称，已通过公司第八届董事会提名委员会资格审查。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120800035000.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0010","BK0020","600420","BK0082","BK0132"],"gpt_icon":0},{"id":"2586202898","title":"国药现代(600420.SH)子公司获盐酸氢吗啡酮注射液药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2586202898","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586202898?lang=zh_cn&edition=full","pubTime":"2025-11-28 16:19","pubTimestamp":1764317996,"startTime":"0","endTime":"0","summary":"智通财经APP讯，国药现代(600420.SH)发布公告，近日，公司全资子公司国药集团工业有限公司(简称国药工业)收到国家药品监督管理局核准签发的盐酸氢吗啡酮注射液《药品注册证书》。氢吗啡酮(Hydromorphone)又名二氢吗啡酮或双氢吗啡酮，是一种半合成的阿片类生物碱，1926年投入临床应用。盐酸氢吗啡酮注射液适用于需使用阿片类药物镇痛的患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1375037.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"国药现代(600420.SH)子公司获盐酸氢吗啡酮注射液药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0132","600420","BK0020","BK0239","BK0010","BK0082"],"gpt_icon":0},{"id":"2585103274","title":"每周股票复盘：国药现代（600420）选举王香芬为职工董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2585103274","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585103274?lang=zh_cn&edition=full","pubTime":"2025-11-23 02:56","pubTimestamp":1763837771,"startTime":"0","endTime":"0","summary":"截至2025年11月21日收盘，国药现代报收于10.18元，较上周的10.73元下跌5.13%。本周，国药现代11月17日盘中最高价报10.74元。国药现代当前最新总市值136.53亿元，在化学制药板块市值排名38/151，在两市A股市值排名1325/5167。本周关注点公司公告汇总：选举王香芬女士为第九届董事会职工代表董事。王香芬女士将与股东会选举产生的非职工代表董事共同组成第九届董事会，任期自董事会正式履职之日起至届满。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112300000694.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0082","BK0020","BK0132","600420","BK0239","BK0010"],"gpt_icon":0},{"id":"2585495211","title":"国药现代（600420）披露选举职工董事公告，11月21日股价下跌2.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2585495211","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585495211?lang=zh_cn&edition=full","pubTime":"2025-11-21 22:28","pubTimestamp":1763735335,"startTime":"0","endTime":"0","summary":"截至2025年11月21日收盘，国药现代报收于10.18元，较前一交易日下跌2.21%，最新总市值为136.53亿元。该股当日开盘10.4元，最高10.45元，最低10.16元，成交额达1.23亿元，换手率为0.89%。公司近日发布公告称，上海现代制药股份有限公司于2025年11月20日召开第四届职工代表大会第五次会议，选举王香芬女士为公司第九届董事会职工代表董事。王香芬女士将与股东会选举产生的非职工代表董事共同组成第九届董事会，任期自董事会正式履职之日起至届满。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112100040225.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0082","BK0020","BK0010","BK0239","600420","BK0132"],"gpt_icon":0},{"id":"2582618648","title":"每周股票复盘：国药现代（600420）将参加三季报业绩说明会","url":"https://stock-news.laohu8.com/highlight/detail?id=2582618648","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582618648?lang=zh_cn&edition=full","pubTime":"2025-11-09 03:22","pubTimestamp":1762629734,"startTime":"0","endTime":"0","summary":"截至2025年11月7日收盘，国药现代报收于10.49元，较上周的10.42元上涨0.67%。本周，国药现代11月7日盘中最高价报10.5元。本周关注点公司公告汇总：国药现代将于2025年11月13日参加上海辖区上市公司三季报集体业绩说明会。上海现代制药股份有限公司将于2025年11月13日（星期四）15:00-16:30，通过上证路演中心以网络文字互动方式参加2025年上海辖区上市公司三季报集体业绩说明会。说明会后可通过上证路演中心查看会议情况。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110900001231.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0082","BK0010","BK0239","600420","BK0020","BK0132"],"gpt_icon":0},{"id":"2581727601","title":"国药现代：公司持续加强与国药控股分销、零售等渠道的合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2581727601","media":"证券日报 ","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581727601?lang=zh_cn&edition=full","pubTime":"2025-11-05 20:33","pubTimestamp":1762345980,"startTime":"0","endTime":"0","summary":"证券日报网讯国药现代11月5日在互动平台回答投资者提问时表示，本着市场化原则，公司持续加强与国药控股分销、零售等渠道的合作，通过在线对接、参与国药控股互联互通等多种方式加强与国药集团内商业板块的联动，力推“工商协同”。（文章来源：证券日报）\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-11-05/doc-infwkiip4124886.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-11-05/doc-infwkiip4124886.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1515","LU0640798160.USD","600420","BK0010","BK0239","BK1500","BK1197","LU1115378108.SGD","BK0082","BK0132","01099","BK0020"],"gpt_icon":0},{"id":"2581352742","title":"国药现代（600420）披露参加2025年上海辖区上市公司三季报集体业绩说明会的公告，11月05日股价上涨0.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2581352742","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581352742?lang=zh_cn&edition=full","pubTime":"2025-11-05 17:21","pubTimestamp":1762334480,"startTime":"0","endTime":"0","summary":"截至2025年11月5日收盘，国药现代报收于10.37元，较前一交易日上涨0.1%，最新总市值为139.08亿元。该股当日开盘10.32元，最高10.39元，最低10.28元，成交额达5491.69万元，换手率为0.4%。上海现代制药股份有限公司将于2025年11月13日（星期四）15:00-16:30，通过上证路演中心以网络文字互动方式参加2025年上海辖区上市公司三季报集体业绩说明会。公司已披露《2025年第三季度报告》，将就经营成果、财务状况等与投资者交流。说明会后可通过上证路演中心查看会议情况。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110500029380.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0010","BK0020","BK0132","600420","BK0239","BK0082"],"gpt_icon":0},{"id":"2580626094","title":"国药现代(600420.SH)控股子公司签署《药品上市许可转让合同》","url":"https://stock-news.laohu8.com/highlight/detail?id=2580626094","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580626094?lang=zh_cn&edition=full","pubTime":"2025-11-03 17:07","pubTimestamp":1762160855,"startTime":"0","endTime":"0","summary":"智通财经APP讯，国药现代 发布公告，为贯彻落实公司中长期发展战略，丰富公司产品管线，公司控股子公司国药致君坪山与安徽美来签署了《药品上市许可转让合同》，安徽美来将其产品乳果糖口服溶液药品上市许可转让予国药致君坪山，转让费总计人民币586.00万元。该事项不会对公司当期经营业绩产生重大影响。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1364504.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["600420","BK0020","BK0010","BK0239","BK0082","BK0132"],"gpt_icon":0},{"id":"2580476516","title":"每周股票复盘：国药现代（600420）Q3净利降45.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2580476516","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580476516?lang=zh_cn&edition=full","pubTime":"2025-11-02 03:36","pubTimestamp":1762025774,"startTime":"0","endTime":"0","summary":"截至2025年10月31日收盘，国药现代报收于10.42元，较上周的10.83元下跌3.79%。本周，国药现代10月27日盘中最高价报10.87元。股本股东变化截至2025年9月30日，国药现代股东户数为3.78万户，较6月30日减少2,102户，减幅5.26%。业绩披露要点国药现代2025年三季报显示，前三季度主营收入69.2亿元，同比下降19.47%；归母净利润8.01亿元，同比下降16.07%；扣非净利润7.39亿元，同比下降20.24%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110200000626.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0010","BK0082","600420","BK0132","BK0020"],"gpt_icon":0},{"id":"2579173912","title":"股市必读：国药现代(600420)股东户数3.78万户，较上期减少5.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579173912","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579173912?lang=zh_cn&edition=full","pubTime":"2025-10-31 02:13","pubTimestamp":1761847990,"startTime":"0","endTime":"0","summary":"截至2025年10月30日收盘，国药现代报收于10.41元，下跌3.7%，换手率2.26%，成交量30.29万手，成交额3.17亿元。交易信息汇总10月30日主力资金净流出4679.45万元，占总成交额14.76%；游资资金净流入4690.59万元，占总成交额14.8%；散户资金净流出11.13万元，占总成交额0.04%。股本股东变化截至2025年9月30日，公司股东户数为3.78万户，较6月30日减少2102户，减幅5.26%。户均持股数量由上期的3.36万股上升至3.54万股，户均持股市值为37.7万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103100002792.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","BK0239","BK0010","BK0020","600420","BK0082"],"gpt_icon":0},{"id":"2579977353","title":"图解国药现代三季报：第三季度单季净利润同比下降45.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579977353","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579977353?lang=zh_cn&edition=full","pubTime":"2025-10-29 19:22","pubTimestamp":1761736929,"startTime":"0","endTime":"0","summary":"证券之星消息，国药现代2025年三季报显示，前三季度公司主营收入69.2亿元，同比下降19.47%；归母净利润8.01亿元，同比下降16.07%；扣非净利润7.39亿元，同比下降20.24%；其中2025年第三季度，公司单季度主营收入20.43亿元，同比下降22.43%；单季度归母净利润1.29亿元，同比下降45.31%；单季度扣非净利润1.02亿元，同比下降58.01%；负债率18.79%，投资收益6828.75万元，财务费用-3914.02万元，毛利率33.29%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102900040251.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600420"],"gpt_icon":0},{"id":"2578493201","title":"国药现代最新公告：公司及下属子公司拟中选第十一批全国药品集中采购","url":"https://stock-news.laohu8.com/highlight/detail?id=2578493201","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578493201?lang=zh_cn&edition=full","pubTime":"2025-10-28 18:31","pubTimestamp":1761647481,"startTime":"0","endTime":"0","summary":"国药现代公告称，公司及部分下属子公司参加了国家组织药品联合采购办公室组织的第十一批全国药品集中采购工作，部分药品拟中选本次集中采购。上述拟中选产品2024年度销售额合计29,100.71万元，占公司2024年度营业收入的比例约为2.66%。拟中选药品的中选价格与原地方性平均中标价格相比存在一定程度下降。上述事项对公司当期经营业绩不会产生重大影响。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102800034874.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0082","BK0132","BK0239","BK0010","600420","BK0020"],"gpt_icon":0},{"id":"2578615371","title":"国药现代最新公告：全资子公司国药容生盐酸林可霉素注射液通过仿制药一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2578615371","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578615371?lang=zh_cn&edition=full","pubTime":"2025-10-27 16:53","pubTimestamp":1761555183,"startTime":"0","endTime":"0","summary":"国药现代公告称，全资子公司国药容生收到国家药监局核准签发的《药品补充申请批准通知书》，批准盐酸林可霉素注射液通过仿制药质量和疗效一致性评价。该药品为系统用抗感染药，适用于治疗由链球菌、肺炎球菌和葡萄球菌等敏感菌株引起的严重感染。该事项对公司目前经营业绩不会产生重大影响，但药品销售受行业政策、招标采购、市场环境等因素影响，存在不确定性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102700022035.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0082","BK0132","600420","BK0010","BK0020"],"gpt_icon":0},{"id":"2576910049","title":"每周股票复盘：国药现代（600420）国药容生法莫替丁注射液通过一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2576910049","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576910049?lang=zh_cn&edition=full","pubTime":"2025-10-19 03:34","pubTimestamp":1760816052,"startTime":"0","endTime":"0","summary":"截至2025年10月17日收盘，国药现代报收于10.67元，较上周的10.77元下跌0.93%。本周，国药现代10月16日盘中最高价报10.85元。该药品为化学药品，注册分类为化学药品，上市许可持有人和生产企业均为国药集团容生制药有限公司。米内网数据显示，2024年全国公立医疗机构法莫替丁注射液销售额约4.13亿元。国药容生累计研发投入约336.49万元。通过一致性评价有利于该产品未来市场拓展和销售，但对当前经营业绩无重大影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101900000713.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600420","BK0132","BK0020","BK0082","BK0239","BK0010"],"gpt_icon":0},{"id":"2576354051","title":"国药现代（600420）披露全资子公司药品通过仿制药一致性评价，10月17日股价下跌1.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2576354051","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576354051?lang=zh_cn&edition=full","pubTime":"2025-10-17 22:34","pubTimestamp":1760711653,"startTime":"0","endTime":"0","summary":"截至2025年10月17日收盘，国药现代报收于10.67元，较前一交易日下跌1.11%，最新总市值为143.1亿元。近日，国药现代发布关于全资子公司药品通过仿制药一致性评价的自愿性信息披露公告。公告显示，公司全资子公司国药集团容生制药有限公司收到国家药品监督管理局核准签发的《药品补充申请批准通知书》，法莫替丁注射液通过仿制药质量和疗效一致性评价。米内网数据显示，2024年全国公立医疗机构法莫替丁注射液销售额约4.13亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101700038580.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0082","BK0132","BK0239","BK0010","600420","BK0020"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1766135447416,"stockEarnings":[{"period":"1week","weight":0.0049},{"period":"1month","weight":-0.0191},{"period":"3month","weight":-0.0525},{"period":"6month","weight":0.0109},{"period":"1year","weight":-0.1196},{"period":"ytd","weight":-0.1145}],"compareEarnings":[{"period":"1week","weight":0.0008},{"period":"1month","weight":-0.0161},{"period":"3month","weight":0.0147},{"period":"6month","weight":0.1537},{"period":"1year","weight":0.1461},{"period":"ytd","weight":0.1565}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海现代制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"37848人(较上一季度减少5.26%)","perCapita":"35435股","listingDate":"2004-06-16","address":"上海市浦东新区建陆路378号","registeredCapital":"134117万元","survey":" 上海现代制药股份有限公司的主营业务是医药产品研发、生产与销售。公司的主要产品是医药中间体、原料药、化学制剂、动物疫苗、大健康。至报告期末，公司累计通过一致性评价项目（含视同）151个，其中通过自主研发和BD项目引进获得新产品批准文号59个。","listedPrice":8.08},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"国药现代(600420)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供国药现代(600420)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"国药现代,600420,国药现代股票,国药现代股票老虎,国药现代股票老虎国际,国药现代行情,国药现代股票行情,国药现代股价,国药现代股市,国药现代股票价格,国药现代股票交易,国药现代股票购买,国药现代股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"国药现代(600420)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供国药现代(600420)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}